PREVENT Equations Classify 15 Million at Elevated Risk for Heart Failure
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 16, 2024 -- The Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations classify 15.0 million U.S. adults as having an elevated risk for heart failure, according to a research letter published online Dec. 17 in the Annals of Internal Medicine.
Jeremy B. Sussman, M.D., from the University of Michigan in Ann Arbor, and colleagues used data from the combined 2017 to March 2020 cycle of the National Health and Nutrition Examination Survey to identify U.S. adults, aged 30 to 79 years, without known cardiovascular disease at elevated risk for heart failure based on the PREVENT equations. For each adult, the estimated 10-year risk for heart failure and atherosclerotic cardiovascular disease (ASCVD) was calculated using PREVENT equations. The study population included 4,872 participants, representing 143.2 million Americans.
The researchers found that the mean estimated 10-year risk for heart failure was 3.7 percent; overall, 15.0 million adults were classified as having intermediate or high (elevated) risk for heart failure. Risk varied with age, with 30- to 39-years-olds and 70- to 79-year-olds accounting for 0.3 and 62.4 percent of the elevated risk group, respectively. Across risk categories, racial and ethnic representation was fairly consistent, although Black adults accounted for 9.7 and 14.2 percent of the low- and elevated-risk groups, respectively. There was a correlation seen between risk for heart failure with ASCVD risk (R2 = 0.83); about 4.6 and 0.9 percent of participants were in a higher and lower heart failure risk category versus ASCVD risk category, respectively. Of those with elevated heart failure risk, 54.3 and 55.6 percent had systolic blood pressure above 130 mm Hg and had body mass index above 30 kg/m2, respectively.
"Developing reliable strategies to identify populations at heart failure risk and implement primary heart failure prevention has the potential for dramatic public health impact," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-18 00:00
Read more
- ACR: Inebilizumab Reduces Risk for Flares in IgG4-Related Disease
- Colon Cancer Rates Are Up Among the Young Worldwide
- Group of Nobel Laureates Press Senate to Reject Kennedy's Nomination
- Flavored Vapes Behind Big Surge in U.S. E-Cigarette Sales
- Celiac Disease Linked to Higher Risk for Developing Alopecia Areata
- Task Force Supports Women Over 30 Collecting Samples for Cervical Cancer Screening
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions